A facility does not become “cGMP” by declaration — it becomes cGMP-compliant by meeting a specific set of design, construction, and operating requirements that FDA and other regulators can inspect and verify, and then by proving through documented qualification that it actually performs as designed. For a research institution, tech transfer office, or contract manufacturer evaluating whether to build, lease, or retrofit space for GMP-grade production — of an investigational drug, a biologic, or a device — understanding what “facility requirements” actually means up front is the difference between a straightforward capital project and a facility that fails its pre-approval inspection.
This guide covers what current Good Manufacturing Practice (cGMP) requires of a physical facility: the regulatory basis, the core design elements inspectors look for, cleanroom classification, qualification and documentation, and how facility requirements differ by product type and by region.
The Regulatory Basis for cGMP Facility Requirements
In the United States, facility requirements for finished pharmaceuticals sit in 21 CFR Part 211, Subpart C (“Buildings and Facilities,” §§ 211.42–211.58). Read together, these sections require a facility to have suitable size, construction, and location; separate or defined areas to prevent mix-ups and contamination between operations; adequate lighting; ventilation with air filtration and, where needed, temperature and humidity control adequate to the operation; potable water and appropriate plumbing with no cross-connection to non-potable systems; sanitary sewage and waste disposal; adequate washing and toilet facilities; and a written sanitation program covering pest control, cleaning, and maintenance of buildings and equipment. For active pharmaceutical ingredients (APIs), the comparable requirements sit in ICH Q7 (Section 4, Buildings and Facilities), which forms the basis of EU GMP Annex 4/EudraLex Volume 4 Part II for API manufacturing. Medical device manufacturing facilities fall instead under the FDA’s Quality Management System Regulation (QMSR, effective February 2, 2026, incorporating ISO 13485:2016 by reference) rather than Part 211 — see CASRAI’s GxP Compliance guide for how GLP, GCP, GMP, and GDP requirements map onto different product types and study phases.
Outside the US, the EU applies EudraLex Volume 4, with Annex 1 (“Manufacture of Sterile Medicinal Products”) governing sterile-product facility design specifically — its revised Principles and most annex provisions took effect August 25, 2023, with the fully revised Annex 1 in force since then and a later transition deadline of August 25, 2024 for some provisions (e.g. Point 8.123 on single-use systems). The World Health Organization publishes its own GMP guidance used as the baseline in many jurisdictions without a mature domestic regulator. These frameworks overlap substantially — separated/defined production areas, controlled air handling, and documented cleaning — but are not identical, and a facility intended to supply multiple markets (e.g. a US sponsor manufacturing investigational product also used in an EU trial) needs to be designed against the strictest applicable requirement, not just the domestic one.
Core Design Elements Inspectors Look For
Regardless of jurisdiction, a cGMP-compliant facility is built around a small number of recurring design principles:
- Separation of operations. Areas with a potential for cross-contamination or mix-up — raw-material receipt and quarantine, weighing/dispensing, different product lines, production versus QC laboratories, and packaging — must be physically separated or otherwise controlled (e.g. by procedure and airlock, where physical separation isn’t practical). This is the single most commonly cited deficiency in FDA Form 483 observations for facility design.
- Unidirectional material and personnel flow. Materials and people should move from “dirty” to “clean” areas, not back and forth, to minimize the chance of contaminating a cleaner zone with a dirtier one. This drives the physical layout — gowning rooms, airlocks, and pass-throughs are placed specifically to enforce one-way flow.
- Controlled HVAC and air filtration. Air handling systems must deliver the air quality (particle count, viable microbial count, temperature, humidity, and pressure differential) appropriate to each room’s classification, and maintain a cascading pressure differential from cleaner to less-clean areas so air leaks outward, not inward, through door gaps.
- Cleanable, non-shedding surfaces. Walls, floors, and ceilings in production areas use smooth, non-porous, coved (rounded, gap-free) finishes that can be cleaned and sanitized without harboring residue or microbial growth.
- Utilities built for purity, not just supply. Water systems (purified water, water for injection), compressed gases, and steam used in the process or that can contact product/product-contact surfaces need their own qualification and monitoring — a facility with excellent air handling but an unvalidated water loop still fails.
- Environmental monitoring infrastructure. Sampling ports, viable/non-viable particle monitoring points, and differential-pressure gauges need to be designed into the space, not added afterward, so ongoing monitoring is actually feasible in routine operation.
See CASRAI’s Cleanroom Checklist for a working checklist against these elements, and HEPA Filter Certification for how the air-filtration piece specifically gets tested and documented.
Cleanroom Classification and Grading
Facility requirements scale with the sterility risk of the product and process step. Two classification systems are used in practice, and a single facility may need to satisfy both if it serves both US and EU markets:
- ISO 14644-1 classifies cleanrooms by maximum permitted airborne particle concentration per class (e.g. ISO Class 5, 7, 8), and is the US pharmaceutical industry’s working reference framework (alongside the older FED-STD-209E classes it superseded). See CASRAI’s Cleanroom Classifications guide for the full class table and equivalencies, and ISO Class 7 Cleanroom Requirements for the specific requirements at the classification level most gowning and filling-support areas are built to.
- EU GMP Annex 1 Grades A–D classify by both particle counts and viable (microbial) limits, at rest and in operation — Grade A being the highest-risk aseptic zone (e.g. the immediate filling area for a sterile product), through Grade D, the lowest-risk controlled background area. Annex 1’s in-operation limits are typically the binding design constraint, since a room has to hold its grade while people and equipment are actively working in it, not just when empty.
A facility’s classification isn’t chosen once and forgotten — it has to be demonstrated on qualification and then re-verified on a defined monitoring schedule for the life of the facility.
Facility Qualification: Proving the Design Works
Meeting design requirements on paper isn’t sufficient — cGMP requires documented evidence that the built facility actually performs to specification. This is done through the standard qualification sequence: Design Qualification (DQ, confirming the design meets user requirements before construction), Installation Qualification (IQ, confirming equipment/systems are installed as specified), Operational Qualification (OQ, confirming systems operate within specified ranges), and Performance Qualification (PQ, confirming the facility performs consistently under actual or simulated production conditions, including worst-case scenarios). CASRAI’s Facility Qualification guide covers the full IQ/OQ/PQ protocol and documentation structure in detail; this is the step that converts a facility requirement (“this room must hold ISO Class 7”) into inspectable proof that it does.
Facility qualification isn’t a one-time event. Ongoing requirements include periodic requalification (particularly after any change to layout, HVAC, or equipment), environmental monitoring trend review, and preventive maintenance of HVAC, water, and utility systems — all of which feed into the facility’s readiness for a GMP audit or an unannounced FDA inspection.
Who Actually Needs a cGMP-Compliant Facility
For most CASRAI readers, this isn’t a day-one concern — it becomes relevant at a specific translational milestone. A standard academic wet lab producing research-grade material does not need to meet Part 211 facility requirements. The trigger is when material moves toward human use: manufacturing drug substance or drug product for an Investigational New Drug (IND) application, producing cell or gene therapy product for a clinical trial, or licensing a process to a partner who will scale it commercially. At that point, an institution typically has three paths: build or retrofit internal GMP space (a multi-year, multi-million-dollar capital project for anything beyond a small Phase 1 suite), contract with a GMP contract manufacturing organization (CMO/CDMO), or use a no-cost federal resource such as NIH NCATS’ BrIDGs program, which gives qualifying academic investigators access to IND-enabling GMP manufacturing support. See CASRAI’s broader Good Manufacturing Practice (GMP) guide for how GMP fits alongside GLP and GCP across the translational research pathway, and Clinical Trial Supply Management for what happens to investigational product once it leaves a qualified facility.
Frequently Asked Questions
What is the difference between GMP and cGMP?
They refer to the same regulatory framework. FDA uses “current” (cGMP) specifically to signal that the required systems, equipment, and technology must be kept up to date with the latest standards and industry practice — a facility built to 1980s specifications that has never been upgraded is not automatically compliant just because it once was. In everyday use, “GMP facility” and “cGMP facility” mean the same thing.
Does a university research lab need to meet cGMP facility requirements?
Not for standard preclinical research. cGMP facility requirements apply specifically to the manufacture of drug substance, drug product, biologic, or device material intended for human use in a clinical trial or for market — the trigger is the IND/IDE filing or a licensing deal, not the research itself. Preclinical safety studies instead fall under Good Laboratory Practice (21 CFR Part 58), a related but distinct framework.
How long does it take to build or qualify a cGMP facility?
There is no fixed timeline — it depends heavily on scope (a single Phase 1 fill-finish suite versus a full commercial manufacturing plant), whether it’s new construction or a retrofit, and the qualification burden for the product’s sterility risk class. Multi-year timelines are typical for a purpose-built facility; retrofitting existing space against a defined URS (user requirements specification) can be faster but still commonly runs 12–24 months once DQ/IQ/OQ/PQ and environmental monitoring trending are factored in.
What is the difference between facility qualification and facility requirements?
Facility requirements are the design and construction standards a facility must meet (separation of operations, air handling, cleanable surfaces, utilities, and so on). Facility qualification is the documented process — DQ/IQ/OQ/PQ — of proving that a specific, built facility actually meets those requirements. Requirements are the target; qualification is the evidence.
